Barely Significant
← all excerpts

CDK4/6 inhibitor rechallenge therapy in advanced breast cancer.

Discov Oncol · 2025 · PMC12830527 · PMID 41420679

2
hedged sentences
closest p
boldest claim

The sentences

showed a trendno p-value reported
Adding the immune therapy avelumab showed a trend of beneficial in median PFS, but there was no statistical difference, and the adverse reaction rate significantly increased, indicating that the addition of immune therapy is worthy of further exploration in this population.

also in 53,322 other papers

Although the addition of the immunotherapeutic agent avelumab showed a trend toward improved median PFS in patients, this improvement did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.